Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2004 | 06-2004 | 03-2004 | 12-2003 | 09-2003 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,480 | 5,940 | 7,453 | 48 | 63 |
| Receivables | N/A | N/A | N/A | N/A | 3 |
| TOTAL | $3,611 | $6,028 | $7,569 | $48 | $66 |
| Non-Current Assets | |||||
| PPE Net | 159 | 168 | 151 | N/A | N/A |
| Other Non-Current Assets | 15 | 13 | 13 | 0 | 3 |
| TOTAL | $174 | $181 | $164 | $N/A | $3 |
| Total Assets | $3,785 | $6,209 | $7,733 | $48 | $68 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,924 | 1,192 | 637 | 33 | 5 |
| Accrued Expenses | 68 | 102 | 136 | 5 | N/A |
| TOTAL | $1,991 | $1,294 | $773 | $38 | $5 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,991 | $1,294 | $773 | $38 | $5 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 47,630 | 39,520 | 39,422 | 39,422 | 1,917 |
| Common Shares | 40 | 40 | 39 | 8 | 2 |
| Retained earnings | -10,593 | -7,340 | -5,265 | -184 | -130 |
| TOTAL | $1,794 | $4,915 | $6,960 | $10 | $63 |
| Total Liabilities And Equity | $3,785 | $6,209 | $7,733 | $48 | $68 |